GLATIRA
Brand:
GLATIRA
Manufacturer:
CIPLA
Manufacturer Details
CIPLA
Compositions:
Glatiramer acetate 20mg per m injection,
|
Strength
|
Rate
|
Packing Style
|
|
20mg per ml
|
374.17
|
vial injection
|
List of Related Indications:
List Of Drugs:
- Glatiramer aceatate - Immunosuppressieves- Immunological Agents- (Feb 2007)
Indication Type Description:
Drug Interaction:
Corticosteroids, Protein bound drugs
Indication:
LIST OF DRUGS DURING 2007
Sr.No- 23
Name of the Drug- Glatiramer Acetate injection
(20mg/ml)
Pharmacological Classification- Multiple sclerosis
Date of Approval- 21-02-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
New drugs approved For Marketing by Drug Controller General of India(DCGI )
during the period January 1988 to November 2014
(Ref- IDMA Annual Publication 2015)
Name of Drug Indication Date of Approval
1.Glatiramer acetate injection 21-02-2007
20mg/ml
Multiple sclerosis
2.Glatiramer acetate injection 20mg/ml 03-06-2009
& Prefilled syringe (20mg/ml)
For the reduction of frequency of relapses in patients with
replasing-remitting mutiple sclerosis
Multiple sclerosis
Adverse Reaction:
Immediate post inj reactions such as vasolidilation, chest pain, dyspnoea, Palpitations, tachycardia Asthenia, nausea, hypertonia, anxiety, headache rash, arthalgia, sweating, tremor, Lymphadenopathy Peripheral or face oedema
Contra-Indications:
Treatment must be initiated under expert supervision Elderly Renal impairment, moniror renal function Monitor for signs of systemic reaction to injection History of cardiovascular disease
Dosages/ Overdosage Etc:
Indication-
Multiple sclerosis
Dosage-
20mg sc inj once daily Not to be given by i.m. or i.v. route Not recommended for patients below 18 years
